Manganese (Mn) exists in a number of physical and chemical forms in the environment, and is an essential trace metal, necessary for normal cellular functioning. 1) In the brain, Mn is a cofactor for some metalloprotein enzymes, including Mn-superoxide dismutase and glutamine synthetase.
like receptors inhibit adenylate cyclase activity. 12) Most studies that have examined the effects of Mn neurotoxicity and dopamine receptors have focused on the D2 receptor, which is implicated in many of the behavioral alterations observed in subjects exposed to Mn. 13) We investigated whether acute exposure to Mn may change motor activity and the expression of TH and the dopamine D2-like receptors D2 (DRD2), D3 (DRD3), and D4 (DRD4) at the mRNA and protein level in the striatum of the mouse brain.
MATERIALS AND METHODS

Animals and Treatment
Experiments were approved by the Institutional Animal Care and Use Committee of Keimyung University, Korea. Experiments were conducted according to the NIH guidelines for the care and use of laboratory animals. Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility, with free access to food and water.
C57BL/6 mice (nϭ24, 8-week-old males, weighing 26.5Ϯ 1.0 g) were divided into three groups: saline-treated control, low-dose manganese-treated (low Mn), and high-dose manganese-treated (high Mn). Animals in the three groups received i.p. injections of saline, 20 mg/kg MnCl 2 · 4H 2 O, or 40 mg/kg MnCl 2 · 4H 2 O, once per day for 5 d, respectively. All animals were euthanized 10 d after the last treatment. Mice and manganese chloride tetrahydrate (MnCl 2 · 4H 2 O) were purchased from DH Biolink (Chungbuk, Korea) and Sigma (St. Louis, MO, U.S.A.), respectively. Other reagents were of the highest quality available and were obtained from commercial sources.
Assessment of Motor Coordinating Performance
Motor coordination of mice was tested using a rota-rod treadmill (IITC Life Science, CA, U.S.A.). The animals were trained on the apparatus for 3 d before the experiment. The accelerating speed of the rota-rod was set to increase from 10 to 30 rpm within 10 s. The animals were placed on the treadmill and the time at which each animal fell from the drum was recorded. The mean time of three trials was used for analysis.
Quantitative Real-Time RT-PCR Ten days after the end of the injection regimen, mice were sacrificed by CO 2 asphyxiation and were decapitated. Brains were rapidly removed on ice and the striatum was quickly dissected on an ice-cold plastic dish. Tissue samples were immediately placed into cryovials and stored at Ϫ70°C until use. For the quantification of mRNA levels of the different receptor subtypes, the striata of three mice in the same treatment group were pooled. Total RNA was extracted from these striata using High Pure RNA tissue kits (Roche Diagnostics), according to the manufacturer's protocol. cDNAs were reversetranscribed from those RNAs using the ReactionReady First Strand cDNA Synthesis Kit (SuperArray Bioscience). The cDNAs from those samples were characterized using a mouse neurotransmitter receptor and regulator PCR array (SuperArray Bioscience) and the RT2 SYBR Green/Fluorescein PCR master mix (SuperArray Bioscience) on a iCycler Real-Time PCR System (BioRad Laboratories). The following genes were analyzed (followed by its NCBI Ref.Seq.): DRD2 (NM_010077), DRD3 (NM_007877), DRD4 (NM_007878), and the reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (NM_001001303). GAPDH, a housekeeping gene, was used for normalization. Data were analyzed using the DDC t method. For each gene, fold-changes were calculated as the difference in gene expression between the striatum from 40 mg/kg Mn-treated mice and control mice.
Preparation of Tissue Extracts and Western Blotting For Western blotting, the striatum was homogenized in RIPA buffer (Sigma) containing 1% protease inhibitor cocktail and a phosphatase inhibitor cocktail. The homogenate was centrifuged (14000 rpm, 40 min) and the supernatant was collected. The protein concentration was estimated by the Bradford method, using bovine serum albumin as the standard. An aliquot of 5 mg protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with the separated protein transferred to a nitrocellulose membrane. For immunoblotting, the following primary antibodies were used: mouse anti-TH monoclonal antibody (1 : 4000 dilution, Chemicon), mouse anti-DRD2 monoclonal antibody (1 : 100 dilution, Santa Cruz Biotechnology), and rabbit anti-DRD3 polyclonal antibody (1 : 100 dilution, Santa Cruz Biotechnology). After incubation with HRP-conjugated secondary antibodies (Amersham Biosciences), the immunoreactive bands were visualized using ECL Western blotting detection reagents (Amersham Biosciences) and X-ray film. Band intensity was measured using the ImageJ program (NIH, Bethesda, MD, U.S.A.). GAPDH was used as a control for immunoblotting.
Statistical Analysis Motor coordination performance and densitometric measurements of TH, DRD2, or DRD3 immunoblotting in the Mn-treated animals were compared with those of controls using a one-way analysis of variance, followed by a post hoc Duncan test. p values Ͻ0.05 were deemed statistically significant. Mean values were calculated, together with the standard error (S.E.) of each mean. All statistical analyses were conducted using the SAS 8.1 computer software (SAS Institute Inc., Cary, NC, U.S.A.).
RESULTS
Motor Activity
Motor coordination is expressed as a percentage of retention time in Fig. 1 . Control mice improved their skill and learned how to remain on the accelerating rotating rod. Compared to controls, Mn treatment did not significantly change retention time on the rota-rod in either group (20 doses of 40 mg/kg resulted in a slight decrease (7.8%) of relative optical intensity, repeated-measures ANOVA revealed no significant overall effect of Mn on TH expression in the striatum of both 20 mg/kg and 40 mg/kg Mn-treated mice. Dopamine D2 Receptors Expression To understand the molecular basis of these behavioral deficits, differences in mRNA expression of the dopamine D2-like receptor between controls and the 40 mg/kg Mn-treated mice were compared using real-time RT-PCR. DRD2 gene expression was approximately two times higher in treated mice, while DRD3 gene expression was nearly 50% lower in treated mice. There was no significant difference in DRD4 gene expression between controls and treated mice (Table 1) . Based on these mRNA expression analysis, we further examined the protein levels of DRD2 and DRD3 using Western blotting. Representative Western blots of TH proteins and quantitative analysis of optical densities following exposure to the low and high doses of Mn are shown in Fig. 2 . Consistent with the mRNA results, protein levels of DRD2 significantly increased (pϽ0.01). However, unlike mRNA expression, there was no significant overall effect of Mn on DRD3 expression in the striatum of either 20 or 40 mg/kg Mn-treated mice.
DISCUSSION
Mn overload may lead to manganism, which is characterized by a complex behavioral syndrome including motor deficits. Although a wide range of neurons may be linked to Mn-induced motor deficits, dopaminergic neurons are of special concern, because dopamine-rich regions, such as the globus pallidus and striatum, are affected in manganese toxicity. 14) Moreover, locomotor and physical activities, which are closely linked to dopaminergic neurotransmission, are often impaired in Mn-intoxicated rodents. 13) Mn alters several biochemical and biophysical processes in dopaminergic neurotransmission, including striatal dopamine concentrations and expression of the dopamine transporter and dopamine receptors. [15] [16] [17] We examined TH protein levels following Mn treatment since TH is the rate-limiting enzyme for catecholamine synthesis and is often used as a marker for dopaminergic neurons. Mn exposure decreased TH protein levels in the caudate and globus pallidus of monkeys exposed to Ն0. , respectively, for 65 d. 18) In this study utilized a shorter exposure period demonstrate that while motor activities were significantly decreased, TH levels were not significantly decreased at the dose levels of this study. Concerning the mechanism of Mn-induced neurotoxicity, the effects of Mn intoxication on the expression of dopamine receptors in the striatum have been examined, but results have been controversial. For example, one study reported that Mn intoxication did not significantly alter DRD2 levels in the striatum of monkeys, 19) while another showed that striatal DRD2 levels markedly decreased in chronic Mn toxicity. 20) We described the behavioral changes and expression of dopamine D2-like receptors induced by acute Mn exposure in mice. Among DR, DRD2 subtype has been postulated to be a key modulator of locomotor function. Accordingly, DRD2 is known to be the primary therapeutic target for the treatment of bradikynesia associated with Parkinson's disease. 21) However, it remains controversial whether up-regulation of DRD2 expression is a risk factor for motor deficit. Iron deficiency decreased locomotor activity and expression of DRD2 in the striatum, 22) whereas the circling motor activity during the postnatal period resulted in down-regulation of the striatal DRD2 mRNA expression in rat. 23) In this study, Mn exposure produced significant decrease in coordination and/or impaired motor learning and up-regulation of striatal DRD2 at the mRNA and protein levels in a dose-dependent manner. These results suggest that Mn-induced decrease in coordination and/or impaired motor learning may be modulated in part by DRD2. However, further studies are needed to fully address the effects of Mn on dopaminergic neurotransmission. It is likely that Mn exposure affects dopamine D1-like receptors, concomitant with the expression of the dopamine transporter, in the striatum. Moreover, because altered expression of dopamine D2-like receptors could also be a secondary response to the release of glutamate or The expression levels of mRNA were normalized to the levels of GAPDH mRNA and fold differences were calculated relative to the control group. dopamine, 24) it is important to determine whether changes in dopamine receptor numbers in the striatum are a primary or secondary effect of Mn treatment.
In conclusion, Mn treatment significantly and reversibly decreased motor activity after 5 d of treatment and this effect remained until 10 d after the end of Mn administration in the dose range of 20-40 mg/kg. Meanwhile, expression of DRD2 in the striatum exhibited dose dependency and statistically significant increases, whereas expression of TH, DRD3, and DRD4 did not change significantly. These data indicate that altered dopamine D2-like receptor homeostasis in the striatum may be a determinant of Mn-induced neurotoxicity.
